<?xml version="1.0" encoding="UTF-8"?>
<p>In a pandemic setting, investigational products (IPs) to be tried would be approved drugs that are repurposed. The selection of IP could be based on 
 <italic>in vitro</italic> evidence of antiviral activity or plausible disease-modifying mechanisms. However, there would be concerns about the use of IP in the absence of additional preclinical evidence of efficacy and safety.[
 <xref rid="ref2" ref-type="bibr">2</xref>] Selection of investigational interventions for Ebola was based on the World Health Organization's (WHO) ethical framework-Monitored Emergency Use of Unregistered Interventions. This framework recommends that supporting data for the intervention's efficacy and safety should be available, at least from laboratory or animal studies.[
 <xref rid="ref3" ref-type="bibr">3</xref>] The recently concluded Lopinavir Trial for Suppression of SARS-Cov-2 in China (LOTUS China) COVID-19 was conducted based on its 
 <italic>in vitro</italic> activity against SARS-Cov. In this trial, lopinavir–ritonavir plus standard care was compared to standard care alone.[
 <xref rid="ref1" ref-type="bibr">1</xref>] Lopinavir–ritonavir group did not show any benefit in primary endpoint – time to improvement – or secondary endpoint – 28-day mortality.
</p>
